H-FABP as a Biomarker in Transient Ischemic Attack.

IF 2.4 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Cardiovascular Translational Research Pub Date : 2025-02-01 Epub Date: 2024-08-19 DOI:10.1007/s12265-024-10552-4

Daisy Guamán-Pilco, Elvira Chocano, Elena Palà, Marcel Lamana-Vallverdú, Anna Penalba, Paula García-Rodríguez, Marta Rubiera, Alejandro Bustamante, Àlex Rovira, Soledad Pérez-Sánchez, Leire Azurmendi, Sandrine Reymond, Jean-Charles Sánchez, Joan Montaner

{"title":"H-FABP as a Biomarker in Transient Ischemic Attack.","authors":"Daisy Guamán-Pilco, Elvira Chocano, Elena Palà, Marcel Lamana-Vallverdú, Anna Penalba, Paula García-Rodríguez, Marta Rubiera, Alejandro Bustamante, Àlex Rovira, Soledad Pérez-Sánchez, Leire Azurmendi, Sandrine Reymond, Jean-Charles Sánchez, Joan Montaner","doi":"10.1007/s12265-024-10552-4","DOIUrl":null,"url":null,"abstract":"<p><p>The study investigates the utility of heart fatty-acid binding protein (H-FABP) in distinguishing TIA from mimics. Data from 175 patients from the StrokeChip multicenter study was retrospectively analyzed. H-FABP level was measured using a rapid point-of-care test. Findings revealed that H-FABP levels were higher in individuals with TIA compared to mimics [3.10 ng/mL (IQR 2.13-4.78) vs. 1.70 ng/mL (IQR 1.23-2.38)] (p < 0.001). The diagnostic performance of H-FABP, assessed using the area under the curve operating characteristic curve (AUC) was 0. 83 (95% CI = 0.76-0.90) for the final model, indicating good discriminative ability. The PanelomiX determined that a combined cutoff of > 1.85 ng/ml for H-FABP, age > 42.5 years, and baseline NIHSS > 3.5 had a 100% of sensitivity and 23.30% of specificity. The study suggests that H-FABP has potential as a TIA diagnostic biomarker. The rapid application of POCT's for H-FABP measurement supports its potential use in emergency departments and primary care settings.</p>","PeriodicalId":15224,"journal":{"name":"Journal of Cardiovascular Translational Research","volume":" ","pages":"40-47"},"PeriodicalIF":2.4000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cardiovascular Translational Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12265-024-10552-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/19 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

The study investigates the utility of heart fatty-acid binding protein (H-FABP) in distinguishing TIA from mimics. Data from 175 patients from the StrokeChip multicenter study was retrospectively analyzed. H-FABP level was measured using a rapid point-of-care test. Findings revealed that H-FABP levels were higher in individuals with TIA compared to mimics [3.10 ng/mL (IQR 2.13-4.78) vs. 1.70 ng/mL (IQR 1.23-2.38)] (p < 0.001). The diagnostic performance of H-FABP, assessed using the area under the curve operating characteristic curve (AUC) was 0. 83 (95% CI = 0.76-0.90) for the final model, indicating good discriminative ability. The PanelomiX determined that a combined cutoff of > 1.85 ng/ml for H-FABP, age > 42.5 years, and baseline NIHSS > 3.5 had a 100% of sensitivity and 23.30% of specificity. The study suggests that H-FABP has potential as a TIA diagnostic biomarker. The rapid application of POCT's for H-FABP measurement supports its potential use in emergency departments and primary care settings.

Abstract Image

查看原文本刊更多论文

作为短暂性脑缺血发作生物标志物的 H-FABP

该研究探讨了心脏脂肪酸结合蛋白 (H-FABP) 在区分 TIA 和模仿症方面的作用。研究人员对中风芯片多中心研究中 175 名患者的数据进行了回顾性分析。H-FABP水平是通过一种快速的床旁检测方法测量的。研究结果显示，与拟态患者相比，TIA 患者的 H-FABP 水平更高[3.10 纳克/毫升（IQR 2.13-4.78) vs. 1.70 纳克/毫升（IQR 1.23-2.38）]（P 1.85 纳克/毫升的 H-FABP、年龄大于 42.5 岁、基线 NIHSS > 3.5 的敏感性为 100%，特异性为 23.30%。该研究表明，H-FABP 具有作为 TIA 诊断生物标志物的潜力。快速应用 POCT 测量 H-FABP 支持其在急诊科和初级保健中的潜在应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Cardiovascular Translational Research CARDIAC & CARDIOVASCULAR SYSTEMS-MEDICINE, RESEARCH & EXPERIMENTAL

CiteScore

6.10

自引率

2.90%

发文量

148

审稿时长

6-12 weeks

期刊介绍： Journal of Cardiovascular Translational Research (JCTR) is a premier journal in cardiovascular translational research. JCTR is the journal of choice for authors seeking the broadest audience for emerging technologies, therapies and diagnostics, pre-clinical research, and first-in-man clinical trials. JCTR''s intent is to provide a forum for critical evaluation of the novel cardiovascular science, to showcase important and clinically relevant aspects of the new research, as well as to discuss the impediments that may need to be overcome during the translation to patient care.